LAKEWOOD, Colo. – May 25, 2023 – Terumo Blood and Cell Technologies today announced the launch of the industry's first apheresis training program specifically designed for cell therapy manufacturers, aimed at optimizing cell therapy production processes.
The training program is designed to help cell therapy manufacturers better understand the apheresis collection process and its impact on downstream cell therapy manufacturing, supporting improved starting material quality and consistency.
"Understanding the nuances of apheresis collection is critical for cell therapy manufacturers seeking to optimize their processes," said a Terumo Blood and Cell Technologies representative. "This first-of-its-kind training program reflects our commitment to supporting the entire cell therapy value chain, from collection through manufacturing."
The program is intended to bridge the gap between apheresis collection practices and cell therapy manufacturing requirements, helping improve outcomes across the industry.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies, a Terumo group company, is a global leader committed to providing high-quality products and services for blood and blood component collection, and for the production of biotherapies, including cell and gene therapies. Together with our partners and customers, we envision and advance a world where blood and cell technologies contribute to the health and well-being of all people.
